Compare BioNano Genomics Inc (BNGO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Wells Fargo & Co — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Wells Fargo & Co trades at $88.61 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 19374.8× BioNano Genomics Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WFC | |
|---|---|---|
Market Cap | $13.66M | $264.66B |
Sector | Health | Financials |
52-Week High | $4.92 | $96.40 |
52-Week Low | $1.06 | $73.42 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Wells Fargo (WFC) trades at $88.53, up 1.12% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.96, beating expectations, and maintains strong profitability with a net income margin of 25.97% and ROE of 13.13%. Recent news highlights the launch of tokenized deposits for corporate clients and a dividend increase to $0.50 per share, reflecting strategic innovation and shareholder returns.
The outlook for WFC is positive, supported by earnings beats, digital banking initiatives, and analyst consensus leaning toward buy. Risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and competitive pressures in the banking sector. The stock offers value with a P/E of 12.72, below industry averages, but investors should monitor execution on growth strategies and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
